Arbutus Biopharma Corp. sell geldnutzer
Start price
10.07.21
/
50%
€2.45
Target price
10.07.22
€1.90
Performance (%)
23.96%
End price
11.11.21
€3.03
Summary
This prediction ended on 11.11.21 with a price of €3.03. The SELL prediction by geldnutzer finished with a performance of 23.96%. geldnutzer has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Arbutus Biopharma Corp. | -0.844% | -0.844% | 80.266% | 50.619% |
iShares Core DAX® | -0.116% | 1.953% | 14.155% | 16.268% |
iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% | 43.377% |
iShares Nikkei 225® | -1.721% | 3.263% | 12.922% | 8.501% |
iShares S&P 500 | -1.527% | 0.194% | 27.117% | 41.752% |
According to geldnutzer what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Differentiated customer and product portfolio
Could be worthwhile Investment >10% per year
Innovative
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Capable Management
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Standard Investments for future growth
Cons
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
very negative Cash Flow expected
Bad rating
Sustainability is little important
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Risky balance sheet
ROE lower than 10% per year
Bad culture
Few uniques
Growths slower than the competition
Little known brand
Increased challenges to pay loans and raise capital
Comments by geldnutzer for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Sell mit Kursziel 1,9
In the thread Trading Arbutus Biopharma Corp.
Sell beendet
Stopped prediction by geldnutzer for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.80
19.11.22
19.11.22
€2.00
19.11.23
19.11.23
-41.00%
20.11.23
20.11.23
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.05
20.09.22
20.09.22
€1.80
20.09.23
20.09.23
36.59%
19.11.22
19.11.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.39
03.08.22
03.08.22
€2.80
03.08.23
03.08.23
-14.19%
20.09.22
20.09.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.37
28.04.22
28.04.22
€2.00
28.04.23
28.04.23
0.74%
03.08.22
03.08.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.03
11.11.21
11.11.21
€2.90
11.11.22
11.11.22
-21.78%
28.04.22
28.04.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.75
19.11.20
19.11.20
€2.90
19.11.21
19.11.21
-11.05%
10.07.21
10.07.21
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.53
28.10.20
28.10.20
€2.10
04.11.21
04.11.21
8.70%
19.11.20
19.11.20
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.76
13.10.20
13.10.20
€2.90
28.10.20
28.10.20
-8.43%
28.10.20
28.10.20
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€5.25
25.07.20
25.07.20
€2.00
13.10.20
13.10.20
-47.37%
13.10.20
13.10.20
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€18.72
02.10.14
02.10.14
€25.17
09.10.14
09.10.14
-9.24%
09.10.14
09.10.14
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected